A district judge blocked sales of Praluent Jan. 5 after Amgen won a lawsuit against Regeneron and Sanofi, alleging Praluent infringed on patents for its own cholesterol drug Repatha.
Joseph LaRosa, JD, general counsel for Regeneron, said the company would continue to defend its case through the appeals process, according to the report. Sanofi spokeswoman Ashleigh Koss told Reuters via email the company was happy the court stayed the order since it gives U.S. patients continued access to Praluent during the appeals process.
Amgen spokeswoman Kristen Davis told Reuters the company respected the court’s decision but felt confident it would win against Regeneron and Sanofi’s appeal.
The order would have gone into effect Feb. 21, according to the report.
More articles on supply chain:
Supply chain tip of the week: 9 questions to test your inventory management IQ
10 statistics on drug, device recalls in Q4
6 quotes from Pfizer CEO on Trump, drug prices and more
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
